247 related articles for article (PubMed ID: 26291461)
1. BCRP/ABCG2 inhibitors: a patent review (2009-present).
Wiese M
Expert Opin Ther Pat; 2015; 25(11):1229-37. PubMed ID: 26291461
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
3. Design of inhibitors of BCRP/ABCG2.
Juvale K; Wiese M
Future Med Chem; 2015 Aug; 7(12):1521-7. PubMed ID: 26293476
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
5. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.
Kühnle M; Egger M; Müller C; Mahringer A; Bernhardt G; Fricker G; König B; Buschauer A
J Med Chem; 2009 Feb; 52(4):1190-7. PubMed ID: 19170519
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
7. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
[TBL] [Abstract][Full Text] [Related]
8. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
10. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
11. QSAR analysis and molecular modeling of ABCG2-specific inhibitors.
Nicolle E; Boumendjel A; Macalou S; Genoux E; Ahmed-Belkacem A; Carrupt PA; Di Pietro A
Adv Drug Deliv Rev; 2009 Jan; 61(1):34-46. PubMed ID: 19135106
[TBL] [Abstract][Full Text] [Related]
12. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
14. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
Darby RA; Unsworth A; Knapp S; Kerr ID; Callaghan R
Cancer Chemother Pharmacol; 2015 Oct; 76(4):853-64. PubMed ID: 26351135
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
Han B; Zhang JT
Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
[TBL] [Abstract][Full Text] [Related]
16. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
Meyer zu Schwabedissen HE; Kroemer HK
Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
[TBL] [Abstract][Full Text] [Related]
18. Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2.
Shafi T; Jabeen I
Curr Cancer Drug Targets; 2017; 17(2):177-190. PubMed ID: 27585695
[TBL] [Abstract][Full Text] [Related]
19. Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
Gozzi GJ; Bouaziz Z; Winter E; Daflon-Yunes N; Honorat M; Guragossian N; Marminon C; Valdameri G; Bollacke A; Guillon J; Pinaud N; Marchivie M; Cadena SM; Jose J; Le Borgne M; Di Pietro A
Drug Des Devel Ther; 2015; 9():3481-95. PubMed ID: 26170632
[TBL] [Abstract][Full Text] [Related]
20. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
Peng H; Dong Z; Qi J; Yang Y; Liu Y; Li Z; Xu J; Zhang JT
PLoS One; 2009 May; 4(5):e5676. PubMed ID: 19479068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
